drugset
drugset / Trial / NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198 ↗

Phase 1 Recruiting 40 enrolled Exscientia AI Limited
NaSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Timeline

Start
2026-04-13
Primary completion
2029-03
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject EXS74539 Unknown — Oral

Indications

gastric cancer head and neck squamous cell carcinoma liver cancer non-small cell lung carcinoma ovarian cancer prostate cancer renal carcinoma small cell lung carcinoma triple-negative breast carcinoma